New Risk • Feb 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪30.9m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Revenue is less than US$1m (₪21k revenue, or US$6.8k). Market cap is less than US$10m (₪30.9m market cap, or US$9.99m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Nov 26
Third quarter 2025 earnings released: ₪0.45 loss per share (vs ₪0.86 loss in 3Q 2024) Third quarter 2025 results: ₪0.45 loss per share (improved from ₪0.86 loss in 3Q 2024). Net loss: ₪2.36m (loss narrowed 41% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Nov 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 94% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Revenue is less than US$1m (₪105k revenue, or US$33k). Minor Risk Market cap is less than US$100m (₪36.1m market cap, or US$11.2m). 공시 • Oct 02
Bolt Biotherapeutics Provides Update on BDC-4182 Bolt Biotherapeutics announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™? ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, Bolt now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the Company is implementing a workforce reduction of approximately 50%, extending its cash runway into 2027. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₪12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (₪105k revenue, or US$31k). Market cap is less than US$10m (₪24.4m market cap, or US$7.30m). New Risk • Aug 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (₪169k revenue, or US$50k). Market cap is less than US$10m (₪23.9m market cap, or US$7.08m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-₪11m). 공시 • May 30
BioLight Life Sciences Ltd., Annual General Meeting, Jul 07, 2025 BioLight Life Sciences Ltd., Annual General Meeting, Jul 07, 2025. Location: co. offices, Israel New Risk • May 29
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₪11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (₪169k revenue, or US$48k). Market cap is less than US$10m (₪25.0m market cap, or US$7.12m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-₪11m). Reported Earnings • May 29
First quarter 2025 earnings released: ₪0.52 loss per share (vs ₪0.09 profit in 1Q 2024) First quarter 2025 results: ₪0.52 loss per share (down from ₪0.09 profit in 1Q 2024). Net loss: ₪2.42m (down ₪2.84m from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Mar 26
Full year 2024 earnings released: ₪1.53 loss per share (vs ₪5.60 loss in FY 2023) Full year 2024 results: ₪1.53 loss per share (improved from ₪5.60 loss in FY 2023). Net loss: ₪7.14m (loss narrowed 73% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. New Risk • Mar 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 45% per year over the past 5 years. Revenue is less than US$1m (₪198k revenue, or US$55k). Market cap is less than US$10m (₪31.7m market cap, or US$8.74m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). 공시 • May 06
Alcon Management S.A. entered into an agreement to acquire BELKIN Vision Ltd. form BioLight Life Sciences Ltd. (TASE:BOLT) and others for ILS 49.1 million. Alcon Management S.A. entered into an agreement to acquire BELKIN Vision Ltd. form BioLight Life Sciences Ltd. (TASE:BOLT) and others for ILS 49.1 million on May 3, 2024. Consideration in the amount of about ILS 9 million in cash and Additional consideration in the amount of up to approximately ILS 40.085 million to be paid, in periodic payments depending on compliance with the requirements through the provisions of the merger agreement in connection with the revenue targets from annual sales of Belkin products by Alcon. Belkin will become a wholly owned subsidiary of Alcon. Completion of the merger transaction is subject to the existence of conditions precedent as is customary in merger transactions of this type, including approval Belkin's general meeting for the merger, correctness of the parties representations and receipt of the merger certificate from the Companies Registry. The merger transaction will be completed no later than 120 days from the date of signing the merger agreement, and it can be extended as is customary in agreements of this type, including with the agreement of the parties or due to a delay in receiving the merger certificate from the Companies Registry same as the merger agreement includes provisions for termination and cancellation of event controls that are accepted in agreements of this type. New Risk • Mar 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₪11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪11m free cash flow). Earnings have declined by 68% per year over the past 5 years. Revenue is less than US$1m (₪118k revenue, or US$32k). Market cap is less than US$10m (₪20.4m market cap, or US$5.53m). Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change). 공시 • Mar 06
BioLight Life Sciences Ltd., Annual General Meeting, Apr 08, 2024 BioLight Life Sciences Ltd., Annual General Meeting, Apr 08, 2024, at 14:00 Israel Standard Time. New Risk • Feb 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪11m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (₪91k revenue, or US$25k). Market cap is less than US$10m (₪23.9m market cap, or US$6.57m). New Risk • Sep 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₪11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪11m free cash flow). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (₪91k revenue, or US$24k). Market cap is less than US$10m (₪28.6m market cap, or US$7.53m). Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. Vice Chairman of the Board Suzana Nahum-Zilberberg was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Nov 17
BioLight Life Sciences Ltd. Ordinary shares to Be Deleted from OTC Equity BioLight Life Sciences Ltd. Ordinary shares (Israel) will be deleted from OTC Equity effective form November 17, 2022, due to Inactive Security. Is New 90 Day High Low • Feb 03
New 90-day high: ₪8.40 The company is up 24% from its price of ₪6.79 on 04 November 2020. The Israeli market is up 18% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 33% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: ₪7.40 The company is up 18% from its price of ₪6.27 on 30 September 2020. The Israeli market is up 26% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: ₪6.01 The company is down 20% from its price of ₪7.53 on 25 June 2020. The Israeli market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period.